Synaptogenix Inc (SNPX)

[Antti]

That's a good comparison. Though, there's one obvious difference. AD space haven't had any treatments that would actually treat the disease and there's a HUGE unmet need. So if we get similar results as in previous trial, EVERYONE will know about it. In other words, it's something that has never happened before and it's hard to foresee what kind of excitement and amount of publicity it would create. Whereas, I don't think that many people know about AXSM and their drug yet.

Other thing is that if we can repeat the previous results, there will be no question about the efficacy anymore. It will be proven beyond reasonable doubt with p<0.001 or p<0.0001. So whatever happens after the current phase 2b, it's probably not about the efficacy anymore but about other things (whatever FDA thinks is important, how quickly they are willing to move etc).